We studied the nature of insulin receptor binding in MCF-7 breast cancer cells. In both intact cells and solubilized receptor preparations, high-affinity insulin binding was seen. However, unlabeled insulin-like growth factor-I (IGF-I) was five-fold more potent in inhibiting "HI-insulin binding than insulin itself.
Introduction
Receptors that have tyrosine kinase activity in their intracellular domain play a key role in both normal and neoplastic cell growth. The insulin receptor (IR)' belongs to the tyrosine-kinase growth factor receptor family (1) (2) (3) , and insulin mediates proliferative responses in a variety of both normal and trans- 1 . Abbreviations used in this paper: IGF-I, insulin-like growth factor-I; IR, insulin receptor; MAB, monoazidobenzoyl; WGA, wheat germ agglutinin.
formed cells (4, 5) . However, the role of the IR molecule in human neoplasia has not yet been established. Recently, we have reported that overexpression of the IR is a characteristic feature ofmany human breast cancer specimens (6) . By using a specific IR radioimmunoassay, we found that the average IR content of human breast cancer specimens was five-to six-fold higher than that of normal (7) . Accordingly, these cells have been employed to study the effect of insulin on the regulation ofgrowth and other cellular functions (8) . However, whether insulin mediates the growth of breast cancer cells via the IR is controversial. On one hand, Osborne, Lippman and colleagues have reported that concentrations of insulin as low as 10 pM stimulate the growth ofMCF-7 cells, an estrogen-sensitive line that contains relatively high levels ofinsulin binding (8, 9) . Further, the effects of insulin on mitogenesis on these cells were not inhibited by the monoclonal antibody a-IR3 (10), a specific antagonist ofthe related insulin-like growth factor-I (IGF-I) receptor ( 11) . These findings have suggested, there- fore, that insulin, via its own receptor, regulates growth in MCF-7 cells. On the other hand, two other groups have reported that much higher concentrations of insulin are needed to stimulate the growth ofthese cells (12, 13) . Since the related ligand, IGF-I, stimulated the growth of MCF-7 cells at much lower concentrations than insulin, and since insulin interacts with IGF-I receptors, these groups concluded that the effect of insulin on the growth ofMCF-7 cells was due to the interaction of insulin with the IGF-I receptor. However, in none of the above studies was insulin binding to receptors in either or other breast cancer cells investigated in detail.
The study of insulin and IGF-I receptors in target cells is complicated both by the similarity of the two ligands, insulin and IGF-I, and the similarity of their two receptors (14) . Also, both atypical and/or alternative IGF-I receptors and IGF-I/IR hybrids have been reported in several cell types (15) (16) (17) (18) . In the for both insulin and IGF-I. This unusual receptor may signal the effects of both insulin and IGF-I.
Methods
The following materials were purchased: Dulbecco's modified Eagle's medium (DME H-21), nonessential amino acids, fetal calf serum (FCS), glutamine, penicillin, streptomycin, and trypsin from using an IGF-I receptor cDNA prepared as previously described (24) .
These were labeled with 100 MACi [32PJCTP by random primers (25) to a specific activity of 109 cpm/ug. The nitrocellulose filters were prehybridized and hybridized as previously described (25 Receptor purification by affinity chromatography
Step 1. Confluent 150-cm2 flasks of MCF-7 cells were solubilized in 50 mM Hepes buffer pH 7.6 containing 1 mg/ml bacitracin, I mM PMSF, and 1% Triton X-100 for 60 min at 4VC. A clear supernatant was obtained by centrifugation at 100,000 g for 35 min at 4VC. The supernatant was then applied to a l-ml WGA agarose column which had been previously equilibrated with WGA column buffer containing 150 mM NaCl, 0.1% Triton X-100, 1 mM PMFS, and 50 mM Hepes, pH 7.6 . Glycoproteins were eluted with the same buffer containing 0.3 M N-acetyl D-glucosamine (26).
Step 2. The fractions with insulin-binding activity were pooled and applied to a 2.5-ml column composed of insulin coupled to Affi-gel 15 (27) . After an 18-h incubation at 4VC, the pass-through of the insulinAffi gel column was collected, the column was washed with 50 mM Tris HC1 buffer, pH 7.4, containing 1 M NaCl, 0.1% Triton X-100, and 1 mM PMFS, and then eluted with 50 mM Na-acetate buffer, pH 5.0, containing 1 M NaCl, 0.1% Triton X-100, and 1 mM PMSF. Fractions were collected in tubes containing 0.1 ml of 1 M Tris-Cl buffer pH 8.
Step 3. The fractions with insulin-binding activity were applied to a column of agarose coupled to monoclonal antibody 51 directed at the human IR a subunit (28) . The pass-through was collected and applied to a WGA column as described in step 1. The column was washed with column buffer composed of 50 mM Hepes, pH 7.6, 1 M NaCl, 0.1% Triton X-100, 1 mg/ml bacitracin, and 1 mM PMSF. The IR was eluted with 1.5 M MgCI2, 0.12 M sodium tetraborate, 0.1% Triton X-100, pH 6.5. Eluted fractions were diluted 10-fold with washing buffer and finally applied to WGA column as described in step 1.
'25I-insulin and '25I-IGF-I binding to affinity-purified, solubilized receptors Insulin-binding activity was measured at each purification step by incubating the receptor preparation at 4°C for 16 h with '25I-labeled porcine insulin (40 pM) in a final volume of 240 Ml of binding buffer (100 mM Hepes, pH 7.9, 120 mM NaCl, 1.2 mM MgCI2, 2 mM MnC12, 2.5 mM KCl, 0.5 mM Na acetate, 1 mM EDTA, 1 mg/ml bacitracin, 10 mg/ml BSA) in the presence or absence of excess unlabeled insulin. Carrier human y-globulin (10 mg/ml) was added to each tube. 0.2 ml of22% polyethyleneglycol (PEG) 6000 was then added and incubated for 15 min at 4°C. After centrifugation, precipitates were washed once with 1 1% PEG and recentrifuged, and the supernatant was discarded and the pellet was counted. Specific binding was obtained by subtracting binding with 1251-insulin plus unlabeled insulin from binding with 251I-insulin alone. Specific 125I-IGF-I binding to soluble receptors was carried out in the same manner.
Tyrosine kinase studies Autophosphorylation of atypical IGF-I receptors. Aliquots (20 Ml) of purified atypical IGF-I receptor preparations obtained as described above, were preincubated with 2 mM MnCl2 and 100 nM of either insulin or IGF-I in a total volume of 25 ,l ofWGA buffer. After 60 min at 20°C, the phosphorylation reaction was initiated by adding ATP (10 AM) and 1 MCi ['y32-P]ATP. After 60 min at 20°C, samples were added to 10 Ml of 4X Laemmli buffer containing 100 mM dithiothreitol and boiled for 5 min. Phosphorylated receptor preparations were analyzed on 7.5% SDS-PAGE under reducing conditions. Radioautograms of the dry gels were obtained as described above. (Fig. 2 A) . Surprisingly, unlabeled IGF-I, which typically competes for '25I-insulin binding to the typical IR with a potency of -1% of insulin (31) ing was carried out with this receptor preparation, high-affinity insulin binding was again seen. As with intact cells, unlabeled IGF-I was more potent than insulin in inhibiting '25I-insulin binding (Fig. 2 B) .
In order to determine whether this unusual '25I-insulin binding observed in MCF-7 cells was seen in other cells, we studied both a nonmalignant human breast epithelial cell line (184) and two human breast cancer cell lines (T-47D and ZR-75-1) (Fig. 3) . In all three cell lines '25I-insulin binding was inhibited by unlabeled insulin with a half-maximum effect occurring at 300, 500, and < 200 pM in 184, T-47D, and ZR-75-1 cells, respectively. In contrast to MCF-7 cells, in these three cell lines, unlabeled IGF-I only weakly competed for '25I-insulin binding;
the potency of unlabeled IGF-I was -1% that of insulin. ( Fig. 4) . At 100 nM (the highest concentration tested) a-IR3 (Fig. 5) .
'251-IGF-I binding to MCF-7 cells. We next studied the binding of 1251I-IGF-I to MCF-7 cells (Fig. 6) . Both unlabeled (Fig. 8) . The precipitates were analyzed by SDS-PAGE after reduction. When membranes were photolabeled with B29-MAB'251-insulin, a labeled band of 120 KD 123456 120-- When membranes were photolabeled with the IGF-I photoprobe, a 120-kD band precipitated by the monoclonal antibody a-IR3 was much more intensely labeled than with the insulin photoprobe. In addition, a very weakly labeled band of -200 kD was also detected. This band most likely is an IGF-I receptor precursor. Precipitation of the labeled 120-kD band by the other antibodies was minimal (Fig. 8, rightpanel) (32) . In a previous study (22) Right: Membranes from HTC-IR cells (expressing human IRs) were photoaffinity-labeled with insulin photoprobe. The labeled membranes were solubilized, reduced and alkylated, and immunoprecipitated with antiserum AP-II as described (22) . photoprobe, solubilized, and, after denaturation, immunoprecipitated with antiserum AP-I. Fig. 9 shows the absence ofthe labeled 120-kD band in the precipitate. Under similar conditions the antiserum AP-II precipitated a highly labeled band of 135 kD from membranes prepared from HTC-IR rat hepatoma cells that have been transfected with human IR cDNA, and express IR (33) . The precipitation ofthe 135-kD band was inhibited by an excess of the synthetic peptide (Fig. 9 ). These data provide further evidence that the binding of insulin to MCF-7 cells predominantly occurred on receptors that were not typical IRs. Two other polyclonal antisera to the IR were studied; an antiserum ARS-2 to the IR from a patient with insulin resistance (22) and an antiserum raised to the carboxyl terminal of the IR (3 subunit (34) . Neither antisera reacted with the MCF-7 receptors photolabeled with B29-MAB-'251-insulin (data not shown).
Purification ofthe atypical IGF-I receptor by affinity chromatography. After MCF-7 cells were solubilized and glycoproteins purified by WGA affinity chromatography, they were subjected to insulin affinity chromatography on insulin-Affigel column. The pass-through of this column contained receptors that bound IGF-I with high affinity (Fig. 10 A) , and this binding was weakly inhibited by insulin (< 1% the potency of IGF-I). The material eluted from the insulin-Affi-gel column was then subjected to affinity chromatography on a column of IR monoclonal antibody MA-51 agarose. The pass-through from this column bound IGF-I with high affinity, but unlike typical IGF-I receptors, this binding was inhibited by insulin with a potency ofabout 10% that of IGF-I (Fig. 10 B) . High-affinity insulin binding was also seen in the fraction, but unlabeled IGF-I was more potent than insulin in inhibiting '251I-insulin binding (data not shown). The receptor eluted from the MA-5 1 affinity column bound insulin with high affinity and this binding was very weakly inhibited by unlabeled IGF-I (Fig.  10 C) . Specific IR radioimmunoassay (30) revealed that the MA-5 1 column absorbed > 99% of the IR immunoreactivity.
Tyrosine kinase activities of the atypical IGF-I receptor. Employing the atypical IGF-I receptor preparation purified by affinity chromatography, we next carried out studies to determine whether this atypical receptor contained figand-stimulated tyrosine kinase activity, a characteristic of typical insulin and IGF-I receptors.
When the atypical receptor was allowed to undergo autophosphorylation and then analyzed by SDS-PAGE under reducing conditions, it contained a labeled band of 103 kD (Fig.  11 A) . The phosphorylation of this 103-kD band increased when the atypical receptor was stimulated with either 100 nM insulin or IGF-I (Fig. 11, left) . This band was significantly larger than the typical 95-kD IR (3 subunit (not shown).
Next, the tyrosine kinase activity of the atypical receptor toward the exogenous substrate, poly(Glu-Tyr) 4:1, was studied. Stimulation of the atypical receptor with both insulin and IGF-I produced a dose-dependent increase of 32P incorporation into poly(Glu-Tyr) 4:1 ( Fig. 1 1, right) In contrast, at this a-IR3 concentration, the effect of insulin was inhibited only by 50-60%.
Discussion
Insulin and IGF-I exert their biological effects on cellular metabolism and growth by binding to their distinct plasma membrane receptors which show many similarities of structure and function. Both are a22 tetramers with two extracellular a subunits that bind the hormone and two transmembrane A subunits that have tyrosine kinase activity (14) . The insulin and type I IGF receptors have a high degree of sequence homology, are similar in molecular size, and signal via activation of tyrosine kinase domains (14, (35) (36) (37) (38) . However, the two receptors functionally are distinct, as assessed by clearly different binding affinities for various ligands (38) and certain anti-receptor antibodies (39) . The cloning and sequencing of cDNAs coding for these two receptors have demonstrated that receptors for insulin and IGF-I are products of separate genes (40, 41) . Insulin and IGF-I themselves have sequence homology and can weakly interact with each other's receptors (31, 42) .
In the present study, several lines ofevidence suggested that the interaction of insulin with MCF-7 cells was predominantly via a receptor that was not the typical insulin receptor. For several reasons, the most likely possibility is that the atypical insulin binding seen in MCF-7 cells was to a receptor that is related to the IGF-I receptor. First, the cross-linking of the B29-MAB-1251-insulin revealed a receptor a subunit of 120 kD, a size which is typical for the human placenta IGF-I receptor a subunit, but is smaller than that of the IR a subunit (C. Yip, unpublished data). Moreover, in autophosphorylation studies the (l subunit was 103 kD, a size which is larger than 95 kD IR ,B subunit. Second, the atypical receptor interacted with the a-IR3, an antibody which is directed toward the IGF-I receptor. Therefore, in addition to the typical IGF-I receptor which binds IGF-I but not insulin, another IGF-I receptor exists which binds both IGF-I and insulin. In other tissues, two groups have reported atypical receptors that have high-affinity binding for both insulin and IGF-I. In fetal muscle, Alexandrides and Smith (46) reported that both insulin and IGF-I at similar concentrations stimulated the phosphorylation of 105-kD receptor (3 subunit which was more closely related to the IGF-I receptor (3 subunit than the IR. Also, in bovine retina preparations, Waldbilling and Chadder (47) reported that labeled insulin binding was inhibited by unlabeled IGF-I with a potency equal to or greater than that of insulin. These results support the concept that two IGF-I receptors may exist: one with high affinity only for IGF-I, and another with high affinity for both IGF-I and insulin. These two receptors could be produced by the same gene via either processing of IGF-I receptor mRNA or by posttranslational modifications of the IGF-I receptor protein. Although the human genome appears to contain only one IR and one IGF-I receptor gene, it is possible that the atypical receptor expressed in MCF-7 cells could be a product of a distinct gene that encodes a receptor protein that has high-affinity binding for both IGF-I and insulin. Further studies, therefore, including purification and cloning will be necessary to understand the biochemical nature ofthis atypical IGF-I receptor in MCF-7 cells and other tissues.
The atypical IGF-I receptor had intrinsic tyrosine kinase and regulated biological functions. Both receptor autophosphorylation and phosphorylation of an exogenous substrate were stimulated by both insulin and IGF-I. Moreover, in MCF-7 cells, both insulin and IGF-I stimulated [3H]thymidine incorporation. a-IR3 blocked all the effects of IGF-I, but only 50-60% of the effects of insulin. These studies suggest therefore that insulin exerts a portion of its effect through its own receptor, and another portion through the atypical receptor. Interestingly, Cullen et al. (10) have reported that ca-IR3 does not block the effects of insulin on cell growth in MCF-7 cells.
In summary, in MCF-7 cells, there are three functionally distinct receptors: a typical insulin receptor, a typical IGF-I receptor, and an atypical IGF-I-like receptor which binds both insulin and IGF-I with high affinity. The presence of these receptors in MCF-7 cells may explain in part the conflicting results concerning the growth effects of insulin on these cells. Further studies, however, will be necessary to understand the role of these receptors in the growth of MCF-7 cells.
